Interferon Lambda as a Potential New Therapeutic for Hepatitis C
作者： Dennis M. Miller , Kevin M. Klucher , Jeremy A. Freeman , Diana F. Hausman , David Fontana
DOI: 10.1111/J.1749-6632.2009.05241.X
关键词:
摘要: Interferon lambdas (IFN-lambda) are Type III interferons with biological activity, including induction of antiviral genes, similar to I IFNs, but signal through a distinct receptor complex. The expression pattern for the IFN-lambda is more cell specific than widely distributed IFN-alpha receptor, suggesting in vivo, may have fewer side effects IFN-alpha, such as less hematologic toxicities. A PEGylated form (PEG-rIL-29) was well tolerated animals and did not result toxicity. Clinical data from initial studies PEG-rIL-29 has demonstrated patients hepatitis C without producing These preclinical early clinical support potential new therapeutic agent treatment C.
harvard.edu
sci-hub.se 参考文章(17)
M Buraglio, I Trinchard-Lugan, A Munafo, M Macnamee, Recombinant Human Interferon-β-1a (Rebif®) vs Recombinant Interferon-β-1b (Betaseron®) in Healthy Volunteers Clinical Drug Investigation. ,vol. 18, pp. 27- 34 ,(1999) , 10.2165/00044011-199918010-00004
A MEAGER, K VISVALINGAM, P DILGER, D BRYAN, M WADHWA, Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine. ,vol. 31, pp. 109- 118 ,(2005) , 10.1016/J.CYTO.2005.04.003
Patricia L. Witt, Barry E. Storer, George T. Bryan, Raymond R. Brown, M Flashner, Anne T. Larocca, C B Colby, E C Borden, Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. Journal of Immunotherapy. ,vol. 13, pp. 191- 200 ,(1993) , 10.1097/00002371-199304000-00006
Paul Sheppard, Wayne Kindsvogel, Wenfeng Xu, Katherine Henderson, Stacy Schlutsmeyer, Theodore E. Whitmore, Rolf Kuestner, Ursula Garrigues, Carl Birks, Jenny Roraback, Craig Ostrander, Dennis Dong, Jinu Shin, Scott Presnell, Brian Fox, Betty Haldeman, Emily Cooper, David Taft, Teresa Gilbert, Francis J. Grant, Monica Tackett, William Krivan, Gary McKnight, Chris Clegg, Don Foster, Kevin M. Klucher, IL-28, IL-29 and their class II cytokine receptor IL-28R Nature Immunology. ,vol. 4, pp. 63- 68 ,(2003) , 10.1038/NI873
Vicente Carreño, Stefan Zeuzem, Uwe Hopf, Patrick Marcellin, W.Graham E. Cooksley, Johan Fevery, Moisés Diago, Rajender Reddy, Marion Peters, Karen Rittweger, Ashok Rakhit, Margarita Pardo, A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B Journal of Hepatology. ,vol. 32, pp. 317- 324 ,(2000) , 10.1016/S0168-8278(00)80078-1
Caroline Sommereyns, Sophie Paul, Peter Staeheli, Thomas Michiels, IFN-Lambda (IFN-λ) Is Expressed in a Tissue-Dependent Fashion and Primarily Acts on Epithelial Cells In Vivo PLOS Pathogens. ,vol. 4, ,(2008) , 10.1371/JOURNAL.PPAT.1000017
Nina Ank, Hans West, Søren R. Paludan, IFN-λ: Novel Antiviral Cytokines Journal of Interferon and Cytokine Research. ,vol. 26, pp. 373- 379 ,(2006) , 10.1089/JIR.2006.26.373
Sergei Kotenko, Raymond Donnelly, The IFN-λ Family (IL-28/29) Anti-inflammatory & anti-allergy agents in medicinal chemistry. ,vol. 5, pp. 279- 285 ,(2006) , 10.2174/187152306778017656
Sean E. Doyle, Heidi Schreckhise, Kien Khuu-Duong, Katherine Henderson, Robert Rosler, Harold Storey, Lena Yao, Hong Liu, Fariba Barahmand-pour, Pallavur Sivakumar, Chung Chan, Carl Birks, Don Foster, Christopher H. Clegg, Perdita Wietzke-Braun, Sabine Mihm, Kevin M. Klucher, Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes Hepatology. ,vol. 44, pp. 896- 906 ,(2006) , 10.1002/HEP.21312
Sabine Mihm, Michael Frese, Volker Meier, Perdita Wietzke-Braun, Jens-Gerd Scharf, Ralf Bartenschlager, Giuliano Ramadori, Interferon type I gene expression in chronic hepatitis C Laboratory Investigation. ,vol. 84, pp. 1148- 1159 ,(2004) , 10.1038/LABINVEST.3700135